Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ad4c9403364a2277dc906d5bc5642e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3f4111205626392f051303e7b8819 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5055 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
filingDate |
2022-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fef5bda34c19970e574d765f9c3c1b79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bdf01361cf0f9ba4f9b6792cec56131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38b3753f8190d311a575df79f34dd098 |
publicationDate |
2022-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2022220390-A1 |
titleOfInvention |
Use of odorant receptor for suppressing lactate-induced m2-type differentiation of tumor-associated macrophages and tumor growth |
abstract |
The present invention relates to use of an odorant receptor for suppressing the lactate-induced M2-type differentiation of tumor-associated macrophages and tumor growth. In particular, the inventors of the present invention assumed that lactate-activated OR Olfr78 would function as a macrophage lactate sensor, and confirmed whether Olfr78 on bone marrow-derived macrophages (BMDMs) detect tumor-derived lactate and lactate-induced M2 polarization. The inventors of the present invention attempted to identify factors detected by Olfr78 in tumor conditioned media (TCM), and discovered that lactate in TCM and acetic acid under some conditions are major factors involved in Olfr78-mediated generation of tumor-friendly M2-TAMs. Finally, it was found that Olfr78 deficiency inhibited tumor progression and metastasis and improved antitumor immunity in vivo (in vivo). According to the present invention, Olfr78-lactate interaction plays a major role in tumor progression, and thus, targeting of the Olfr78-lactate axis can be effectively used in targeted cancer therapy. |
priorityDate |
2021-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |